Background: Previous meta-analyses of non-randomized studies suggested that the hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) combination therapy was s
Prof. Busuttil (Figure 1) previously served as the Co-Chairman of the Inteational Congress on immunosuppression and is past President for the American Society o